The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids

Abstract

ObjectiveTo evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months.MethodsWe conducted a randomized, double‐blind, placebo‐controlled, phase II study of RA patients. Patients received placebo, denosumab 60 mg, or denosumab 180 mg every 6 months for 12 months and were followed up for an additional 12 months after …

Authors

Saag KG; McDermott MT; Adachi J; Lems W; Lane NE; Geusens P; Stad RK; Chen L; Huang S; Dore R

Journal

Arthritis & Rheumatology, Vol. 74, No. 4, pp. 604–611

Publisher

Wiley

Publication Date

4 2022

DOI

10.1002/art.41981

ISSN

2326-5191

Associated Experts

Jonathan Derrick Adachi

Professor Emeritus, Faculty of Health Sciences

Visit profile

View published work (Non-McMaster Users)

View published work (McMaster Users)